BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7752070)

  • 1. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.
    Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists.
    Jiang Q; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1107-13. PubMed ID: 7511163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological study of 14 beta-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normor phinone (N-CPM-TAMO).
    Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1021-7. PubMed ID: 7680715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
    McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
    Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO).
    Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1992 Aug; 262(2):526-31. PubMed ID: 1380079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
    Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
    J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 14 beta-Chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists.
    McLaughlin JP; Sebastian A; Archer S; Bidlack JM
    Eur J Pharmacol; 1997 Feb; 320(2-3):121-9. PubMed ID: 9059844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys.
    Gatch MB; Negus SS; Mello NK; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1282-9. PubMed ID: 8819513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
    Tseng LF; Collins KA
    J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
    Takemori AE; Portoghese PS
    J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
    Mjanger E; Yaksh TL
    J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of morphine antinociception by swim-stress in the mouse: involvement of supraspinal opioid delta-2 receptors.
    Vanderah TW; Wild KD; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Hruby VJ; Mosberg HI; Porreca F
    J Pharmacol Exp Ther; 1993 Oct; 267(1):449-55. PubMed ID: 8229774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinociceptive profile of biphalin, a dimeric enkephalin analog.
    Horan PJ; Mattia A; Bilsky EJ; Weber S; Davis TP; Yamamura HI; Malatynska E; Appleyard SM; Slaninova J; Misicka A
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1446-54. PubMed ID: 8389867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
    Cichewicz DL; Martin ZL; Smith FL; Welch SP
    J Pharmacol Exp Ther; 1999 May; 289(2):859-67. PubMed ID: 10215664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.